Therapeutic options for treating major depression, and the role of venlafaxine

Pharmacotherapy

Volumn 16, Issue 3 I, 1996, Pages 352-365

  Scott, Mollie A ^a,b   Shelton, Penny S ^a,c   Gattis, Wendy ^d  

^a CAMPBELL UNIVERSITY   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c Dorothea Dix Hospital   (United States)

^d DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; BARBITURIC ACID DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DESIPRAMINE; DIAZEPAM; DOXEPIN; FLUOXETINE; HISTAMINE H2 RECEPTOR ANTAGONIST; IMIPRAMINE; LITHIUM; MAPROTILINE; METOCLOPRAMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PHENELZINE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIAZIDE DIURETIC AGENT; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE;

ANOREXIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; HUMAN; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SOMNOLENCE; TREATMENT OUTCOME; VERTIGO; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DEPRESSIVE DISORDER; HUMANS;

EID: 0030014907     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. American Psychiatric Association. Practice guideline for major depressive disorders in adults. AmJ Psychiatry 1993;150(suppl 4):1-26.
2. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry 1993;54:405-18.
3. Katon W. The epidemiology of depression in medical care. Int J Psychiatry Med 1987;17:93-112.
4. Blazer D. Depression in the elderly. N Engl J Med 1989;320:164-6.
5. Koenig HG, Cohen HJ, Blazer DG, Meador KG, Westlund R. A brief depression scale for use in the medically ill. Int J Psychiatry Med 1992;22(2):183-95.
6. Depression Guideline Panel. Depression in primary care: detection and diagnosis. Clinical practice guideline 5, vol 1. AHCPR pub. no. 93-0550. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1993.
7. Depression Guideline Panel. Depression in primary care: treatment of major depression. Clinical practice guideline 5, vol 2. AHCPR pub. no. 93-0551. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1993.
8. Stokes PE. Current issues in the treatment of major depression. J Clin Psychopharmacol 1993;13(suppl 2):2S-9.
9. Richelson E. Biological basis of depression and therapeutic relevance. J Clin Psychiatry 1991;52(suppl 6):4-10.
10. Siever LJ, Davis KL. Overview: toward a dysregulation hypothesis of depression. Am J Psychiatry 1985;142:1017-31.
11. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965;122:509-22.
12. Coppen A, Prange AJ, Hill C, Whybrow PC, Noguera R. Abnormalities of indolamines in affective disorders. Arch Gen Psychiatry 1972;26:474-8.
13. Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr. Treatment with antidepressants. In: Retford DC, ed. Principles and practice of psychopharmacotherapy. Baltimore: Williams & Wilkins, 1993:209-92.
14. Carroll BJ. Biologic markers and treatment response. J Clin Psychiatry 1983;44(8):30-40.
15. Ostrow DG, Okonek A, Gibbons R, Cooper R, Davis J. Biologic markers and antidepressant response. J Clin Psychiatry 1983;44(9):10-13.
16. Reiss D, Plomin R, Hetherington EM. Genetics and psychiatry: an unheralded window on the environment. Am J Psychiatry 1991;148(3):283-91.
17. Koenig HG, Blazer DG. Depression and other affective disorders. In: Cassel CK, Riesenberg DE, Sorensen LB, Walsh JR, eds. Geriatric medicine, 2nd ed. New York: Springer-Verlag, 1990:473-90.
18. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: Author, 1994.
19. Wells BG, Hayes PE. Depressive disorders. In: DiPiro JT, Talbert RL, Hayes PE, et al, eds. Pharmacotherapy: a pathophysiologic approach, 2nd ed. New York: Elsevier, 1992:1065-83.
20. Ganzini L, Walsh JR, Millar SB. Drug-induced depression in the aged. Drugs Aging 1993;3(2):147-58.
21. Zimmerman M, Coryell W, Pfohl B. Melancholic subtyping: a qualitative or quantitative distinction? Am J Psychiatry 1986;143:98-100.
22. Keller MB, Lavori PW, Endicott J, Coryell W, Merman GL. Double depression: two-year follow-up. Am J Psychiatry 1983;140:689-94.
23. Rabins PV, Pearlson GD, Strauss ME. Cognitive impairment in psychiatric syndromes. In: Whitehouse PJ, ed. Dementia. Philadelphia: FA Davis, 1993:359-71.
24. Mendels J. Clinical management of the depressed geriatric patient: current therapeutic options. Am J Med 1993;94(suppl 5A):13S-18.
25. Yesavage JA. Depression in the elderly: how to recognize masked symptoms and choose appropriate therapy. Postgrad Med 1992;91(1):255-61.
26. German PS, Shapiro S, Skinner EA, et al. Detection and management of mental health problems of older patients by primary care providers. JAMA 1987;257:489-93.
27. Zung W. A self-rating depression scale. Arch Gen Psychiatry 1965;12:63-70.
28. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71.
29. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Applied Psychological Measurement 1977;1(3):385-401.
30. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychiatry 1967;6:278-96.
31. Yesavage JA. Geriatric depression scale. Psychopharmacol Bull 1988;24:709-11.
32. Montgomery AS, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
33. Sotsky SM, Glass DR, Shea MT, et al. Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH treatment of depression collaborative research program. Am J Psychiatry 1991;148(8):997-1008.
34. Crowe RR. Electroconvulsive therapy: a current perspective. N Engl J Med 1984;311:163-7.
35. Heshe J, Roeder E. Electroconvulsive therapy in Denmark. Br J Psychiatry 1976;128:241-5.
36. Andrews JM, Nemeroff CB. Contemporary management of depression. Am J Med 1994;97(suppl 6A):6S-24.
37. Olin BR, ed. Facts and comparisons, monthly update. St. Louis: Facts and Comparisons, 1995.
38. Potter WZ, Rudorfer MV, Manji H. The pharmacologie treatment of depression. Drug Therapy 1991;325(9):633-41.
39. Callies AL, Popkin MK. Antidepressant treatment of medicalsurgical inpatients by non-psychiatric physicians. Arch Gen Psychiatry 1987;44:157-60.
40. Guscott R, Grof P. The clinical meaning of refractory depression: a review for the clinician. Am J Psychiatry 1991;H8(6}:695-704.
41. Extein IL, Gold MS. Thyroid hormone potentiation of tricyclic antidepressants. In: Extein IL, ed. Treatment of tricyclic-resistant depression. Washington, DC: American Psychiatric Press, 1989:27-48.
42. Katon W, Raskind M. Treatment of depression in the medically ill with methylphenidate. Am J Psychiatry 1980;137:963-5.
43. Price LH. Lithium augmentation in tricyclic-resistant depression. In: Extein IL, ed. Treatment of tricyclic-resistant depression. Washington, DC: American Psychiatric Press, 1989:49-80.
44. Louie AK, Lannon RA, Ajari LJ. Withdrawal reaction after sertraline discontinuation. Am J Psychiatry 1994;151:450-1.
45. Dominguez RA, Goodnick PJ. Adverse events after the abrupt discontinuation of paroxetine. Pharmacotherapy 1995;15(6):775-780.
46. Semla TP, Beizer JL, Higbee MD. Geriatric dosage handbook. Hudson, OH: Lexi-Comp, 1993.
47. Preskom SH. Recent pharmacologic advances in antidepressant therapy for the elderly. AmJ Med 1993;94(suppl 5A):2S-12.
48. Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987;316:363-9.
49. Classman AH, Preud'homme XA. Review of the cardiovascular effects of heterocyclic antidepressants. J Clin Psychiatry 1993;54(2, suppl):16-22.
50. Preskorn SH, Fast GA. Tricyclic antidepressant-induced seizures and plasma drug concentrations. J Clin Psychiatry 1982;43:151-6.
51. Rosenstein DL, Nelson JC, Jacobs SC. Seizures associated with antidepressants: a review. J Clin Psychiatry 1993;54:289.
52. Salzman C. Monoamine oxidase inhibitors and atypical antidepressants. Clin Geriatr Med 1992;8(2):335-48.
53. Brown CS, Bryant SG. Monoamine oxidase inhibitors: safety and efficacy issues. Drug Intell Clin Pharm 1988;22:232-5.
54. Bryant SG, Ereshefsky L. Trazodone: review and evaluation of its antidepressant properties. Clin Pharm 1982;1:406-17.
55. Aronoff GM. Trazodone associated with priapism. Lancet 1984;1:856.
56. Ellingrod VL, Perry PJ. Nefazodone: a new antidepressant. Am J Health Syst Pharm 1995;52:2799-812.
57. Fontaine R. Novel serotonergic mechanisms and clinical experience with nefazodone. Clin Neuropharmacol 1992;15(suppl 1):99A
58. Davidson J. Seizures and bupropion: a review. J Clin Psychiatry 1989;50:256-61.
59. Rickeis K, Schweizer E. Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry 1990;51(12, suppl B):9-12.
60. Grimsley SR, Jann MW. Paroxetine, sertraline, and fluvoxemine: new selective serotonin reuptake inhibitors. Clin Pharm 1992;11:930-57.
61. Montgomery SA. Venlafaxine: a new dimension in antidepressant pharmacotherapy. J Clin Psychiatry 1993;54:119-26.
62. Wyeth-Ayerst. Venlafaxine (Effexor) package insert. Philadelphia, PA; 1995.
63. Muth EA, Haskins JT, Moyer JA, Husbands GEM, Nielsen ST, Sigg EB. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986;35:4493-7.
64. Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol 1992;32:716-24.
65. Anonymous. Venlafaxine - a new antidepressant. Med Lett 1994;36:49-50.
66. 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 1993;23:349-59.
67. Troy SM, Schultz RW, Parker VD, Chiang ST, Blum RA. The effect of renal disease on the disposition of venlafaxine. Clin Pharmacol Ther 1994;56:14-21.
68. Saletu B, Grunberger J, Anderer P, Linzmayer L, Semlitsch HV, Magni G. Pharmacodynamics of venlafaxine evaluated by EEC brain mapping, psychometry and psychophysiology. J Clin Pharmacol 1992;33:589-601.
69. Guy W, ed. ECDEU assessment manual for psychopharmacology, revised. DHEW pub. no. (ADM) 76-338. Rockville, MD: National Institutes of Mental Health, 1976.
70. Derogatis LR, Lipman RS, Rickels K, et al. The Hopkins symptom checklist (HSCL): a self report symptom inventory. Behav Sci 1974;19:1-15.
71. Goldberg HL, Finnerty R. An open-label, variable-dose study of Wy-45,030 (venlafaxine) in depressed outpatients. Psychopharmacol Bull 1988;24:198-9.
72. Schweizer E, Clary C, Weise C, Rickels K. An open-label, dose-finding study of Wy-45,0303, a novel bicyclic antidepressant. Psychopharmacol Bull 1988;24:195-7.
73. Schweizer E, Weise C, Clary C, Fox I, Rickels K. Placebo-controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol 1991;11:233-6.
74. Khan A, Fahre LF, Rudolph R. Venlafaxine in depressed outpatients. Psychopharmacol Bull 1991;27:141-4.
75. Mendels J, Johnston R, Mattes J, Riesenberg R. Efficacy and safety of b.i.d doses of venlafaxine in a dose-response study. Psychopharmacol Bull 1993;23:169-74.
76. Schweizer E, Feighner J, Mandos LA, Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994;55:104-8.
77. Cunningham LA, Borison RL, Carman JS, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994;14:99-106.
78. Clerc GE, Ruimy P, Verdeau-Pailles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994;9:139-43.
79. Shrivastava RK, Cohn C, Crowder J, et al. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 1994;14:322-9.
80. Guelfi JD, White C, Magni G. A randomized, double blind comparison of venlafaxine and placebo in inpatients with major depression and melancholia [abstr]. Clin Neuropharmacol 1992;15(suppl 1):323B.
81. Samuelian JC, Tatossian A, Hackett D. A randomised, double-blind, parallel group comparison of venlafaxine and clomipramine in outpatients with major depression [abstr]. Clin Neuropharmacol 1992;15(suppl 1):324B.
82. Tiller J, Johnson G, O'Sullivan B, Evans L, George T, Yeatman R. Venlafaxine: a long term study [abstr]. Clin Neuropharmacol 1992;15(suppl 1):342B.
83. Nierenberg AA, Feighner JP, Rudolph R, et al. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14:419-23.
84. Morton WA, Sonne SC, Verga MA. Venlafaxine: a structurally unique and novel antidepressant. Ann Pharmacother 1995;29:387-95.
85. Devane CL. Pharmacokinetics of the newer antidepressants: clinical relevance. Am J Med 1994;97(suppl 6A):13S-23.
86. Otton SV, Ball SE, Cheung SW, Inaba T, Sellers EM. Comparative inhibition of the polymorphic enzyme CYP2D6 by venlafaxine (VF) and other 5HT uptake inhibitors. Clin Pharmacol Ther 1994;55:141.
87. Troy S, Pietgies A, Lucki I, et al. Venlafaxine pharmacokinetics and pharmacodynamics. Clin Neuropharmacol 1992;15(suppl 1):324B.
88. Troy SM, Lucki I, Peirgies AA, Parker VD, Klockowski PM, Chiang ST. Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. J Clin Pharmacol 1995;35:410-19.
89. Wyeth-Ayerst. Data on file. Philadelphia, PA, 1995.
90. Rudolph RL, Derivan AT, Pederson R. Quality of life: assessment in drag development. New Research Program and Abstracts 1992; 201:23.
91. Cardinale VA, ed. Drug topics red book. Montrose, NJ: Medical Economics Data, 1995.